Answers are grounded in this paper and cite their sources.
Induction Chemotherapy and Post-Remission Imatinib Therapy for de Novo BCR-ABL-Positive AMLTo the Editor: Translocation t(9;22)(q34;q11) is found in 1-2% of newly diagnosed patients with de novo AML.The prognosis of Ph þ AML is very poor with a median survival time of only 7 months.We present two patients with de novo Ph þ AML who received induction chemotherapy and post-remission imatinib therapy.A 73-year-old man was admitted in November 2003 with fatigue and palpitation.Physical examination showed only pallor.The Hb was 83 g/L, platelets 145 Â 10 9 /L, and WBC 1.4 Â 10 9 /L, 0.12 Â 10 9 /L blast cells.FACS analysis of marrow mononuclear cells showed 22% blast cells positive for HLA-DR, CD34, CD117, CD13, CD33, MPO, and CD38 and partially CD11b.
No takes yet. Share an insight, caveat, or question.
Lazarević et al. (2006) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: